# Development and translation of a novel radioligand to measure pathological changes in glucocorticoid receptor expression in the brain

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $633,938

## Abstract

Project Abstract
The goal of this project is to develop a brain permeable radioligand targeting the glucocorticoid receptor (GR).
A non-steroidal ligand with sub-nanomolar affinity for GR will be radiofluorinated in specific aim 1, and its
pharmacology will be assessed in vitro. Specific binding for GR will be determined in vivo in mice during
specific aim 2. Rat dosimetry estimates and toxicity will also be calculated for an eIND application. In specific
aim 3, a first in man study will be conducted to determine human dosimetry. The data from this project will
confer upon the community a new translational imaging tool to study the role of GR expression changes in
severe mood disorders like depression.

## Key facts

- **NIH application ID:** 9825561
- **Project number:** 5R01MH115043-03
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Michael John Evans
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $633,938
- **Award type:** 5
- **Project period:** 2017-12-01 → 2021-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9825561

## Citation

> US National Institutes of Health, RePORTER application 9825561, Development and translation of a novel radioligand to measure pathological changes in glucocorticoid receptor expression in the brain (5R01MH115043-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9825561. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*